---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018141"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:47:29.412774+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals: Oral Mira-55 normalized pain, reduced inflammation, outperforming injected morphine

## Summary
- Oral Mira-55 normalized pain thresholds to baseline and reduced paw edema in formalin-induced chronic pain model, outperforming injected morphine.
- Mira-55 showed direct CB2-receptor-mediated anti-inflammatory effect; morphine only partial indirect effect.
- First study to directly measure inflammation alongside pain; supports planned IND for chronic inflammatory pain.
- Company targeting $70 billion non-opioid pain market with dual-mechanism drug addressing both cause and perception of pain.

## SEC filing metadata
- accession: 0001493152-25-018141
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315225018141/0001493152-25-018141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315225018141/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018141
- JSON: https://secwatch.observer/filing/0001493152-25-018141.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.